Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial - PubMed
6 hours ago
- #PPARδ agonist
- #pruritus
- #quality of life
- Seladelpar improved pruritus severity and distribution in patients with primary biliary cholangitis (PBC) and pruritus.
- Itch-related sleep disturbance was consistently improved with seladelpar treatment across patient populations.
- Seladelpar improved measures of fatigue compared to placebo in patients with severe itch at baseline.
- Patients without itching tended to remain free from itching with seladelpar, with fewer adverse events of pruritus.
- Seladelpar is a potent and selective PPARδ agonist showing anticholestatic effects and quality-of-life benefits in PBC.